Use of an interferon-gamma based assay to assess bladder cancer patients treated with intravesical BCG and exposed to tuberculosis

Clin Biochem. 2007 Aug;40(12):913-5. doi: 10.1016/j.clinbiochem.2007.04.006. Epub 2007 Apr 27.


Objective: Compare the QuantiFERON-TB Gold In-Tube (QFT) assay and the tuberculin skin test (TST) in bladder cancer patients receiving high dose BCG therapy (BCG patients).

Design and methods: BCG patients and healthy visitors, both exposed to tuberculosis, were screened with a TST and QFT.

Results: QFT-TST correlation was excellent in visitors, but poor in BCG patients. BCG therapy predicted a positive TST (p<0.001) but not a positive QFT (p=0.35).

Discussion: The management of BCG patients was impacted, by measuring the QFT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravesical
  • Aged
  • BCG Vaccine / administration & dosage*
  • BCG Vaccine / therapeutic use*
  • Biological Assay / methods*
  • Female
  • Humans
  • Interferon-gamma / metabolism*
  • Male
  • Tuberculosis / complications*
  • Urinary Bladder Neoplasms / diagnosis*
  • Urinary Bladder Neoplasms / drug therapy*


  • BCG Vaccine
  • Interferon-gamma